Open AccessEffcacy and safety of nerve growth factor for the treatment of neurological diseases: a meta-analysis of 64 randomized controlled trials involving 6,297 patients
Author(s) -
Meng Zhao,
Xiaoyan Li,
Chunying Xu,
LiPing Zou
Publication year - 2015
Publication title -
neural regeneration research/neural regeneration research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.93
H-Index - 38
eISSN - 1876-7958
pISSN - 1673-5374
DOI - 10.4103/1673-5374.156989
Subject(s) - medicine , nerve growth factor , nerve conduction velocity , randomized controlled trial , cochrane library , clinical trial , peripheral nerve injury , meta analysis , anesthesia , surgery , sciatic nerve , receptor
China is the only country where nerve growth factor is approved for large-scale use as a clinical medicine. More than 10 years ago, in 2003, nerve growth factor injection was listed as a national drug. The goal of this article is to evaluate comprehensively the efficacy and safety of nerve growth factor for the treatment of neurological diseases.